Copyright: ©Author(s) 2026.
World J Hepatol. Oct 27, 2026; 18(10): 124793
Published online Oct 27, 2026. doi: 10.4254/wjh.124793
Published online Oct 27, 2026. doi: 10.4254/wjh.124793
Table 5 Autoantibody profile and discriminatory value in the diagnosis of autoimmune hepatitis vs lupus hepatitis in patients with systemic lupus erythematosus
| Autoantibody | Sensitivity in AIH | Specificity for AIH | Prevalence in SLE | Discriminatory value in AIH-SLE | Clinical notes |
| ANA | 80% | Low | 95%-99% | None | Intrinsic to SLE; not useful for discrimination |
| Anti-SMA (VG/VGT) | 63% | Moderate | Approximately 4.4% | High | VG/VGT immunofluorescence pattern strongly favours AIH; anti-F-actin ELISA: AUROC 0.88 |
| Anti-SLA/LP | 14%-20% | 99% | Not reported | Very high | Only AIH-specific autoantibody; sole marker in 14%-20% of AIH; associated with higher biochemical response rates; target antigen: SepSecS |
| Anti-LKM1 | 3% (type 2 AIH) | High | Rare | High if present | Marker of type 2 AIH; predominantly paediatric; target antigen: CYP2D6 |
| Anti-ribosomal P | 0% | High for lupus hepatitis | 10%-40% | High-favours lupus hepatitis | Present in 68.8% of lupus hepatitis vs 0% of primary AIH; OR approximately 5.4 for hepatic SLE involvement (meta-analysis) |
| Polyreactive IgG | 75%-88% (including seronegative AIH) | High | Not studied | Potentially high | 25%-14% higher specificity than ANA/SMA; present in 88% of seronegative AIH; returns to baseline on treatment; not studied in SLE-AIH overlap |
| Anti-MRPS27 | 61.8% | 87.1% | Not studied | Unknown | Novel biomarker identified by human proteome microarray; titres unchanged with treatment; role in AIH-SLE overlap unexplored |
- Citation: Elghezewi A, Mohamed M. Autoimmune hepatitis in the context of systemic lupus erythematosus: A narrative review of overlap syndrome and lupus-associated hepatitis. World J Hepatol 2026; 18(10): 124793
- URL: https://www.wjgnet.com/1948-5182/full/v18/i10/124793.htm
- DOI: https://dx.doi.org/10.4254/wjh.124793